| 4.53 0.27 (6.34%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.07 | 1-year : | 18.08 |
| Resists | First : | 11.19 | Second : | 15.47 |
| Pivot price | 7.74 |
|||
| Supports | First : | 4.26 | Second : | 3.54 |
| MAs | MA(5) : | 5.25 |
MA(20) : | 8.69 |
| MA(100) : | 13.82 |
MA(250) : | 33.28 |
|
| MACD | MACD : | -1 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 3.2 |
D(3) : | 4.6 |
| RSI | RSI(14): 33.5  |
|||
| 52-week | High : | 132.5 | Low : | 0.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ JAGX ] has closed above bottom band by 20.0%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.31 - 5.34 | 5.34 - 5.36 |
| Low: | 4.2 - 4.23 | 4.23 - 4.25 |
| Close: | 4.22 - 4.26 | 4.26 - 4.3 |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Wed, 21 May 2025
Jaguar Health (JAGX) Announces Direct Offering and Private Placement | JAGX Stock News - GuruFocus
Wed, 21 May 2025
Jaguar Health Prices Offering of Shares, Warrants - marketscreener.com
Wed, 21 May 2025
Jaguar Health Secures Fresh Capital: $1.5M Direct Offering Plus Warrants - Key Terms Revealed - Stock Titan
Wed, 21 May 2025
SEC Form 424B5 filed by Jaguar Health Inc. - Quantisnow
Mon, 19 May 2025
JAGX: Jaguar Health Coverage Initiated with Buy Rating | JAGX Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 12.7 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 36 (K) |
| EPS | -130.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.78 |
| Profit Margin | 0 % |
| Operating Margin | -232.5 % |
| Return on Assets (ttm) | -37 % |
| Return on Equity (ttm) | -565.8 % |
| Qtrly Rev. Growth | 52.5 % |
| Gross Profit (p.s.) | 14.43 |
| Sales Per Share | 17.34 |
| EBITDA (p.s.) | -42.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0.26 |
| Price to Cash Flow | -0.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|